Literature DB >> 17136958

Outcome in adult bronchiectasis.

Paul T King1, Stephen R Holdsworth, Nicholas J Freezer, Elmer Villanueva, Martin Gallagher, Peter W Holmes.   

Abstract

The outcome in adult bronchiectasis has not been well described; in particular there has been a lack of long-term prospective studies. Therefore a follow-up study was performed to assess outcome in bronchiectasis in a cohort of adult patients. One hundred-and-one sequential adults, 33 male and 68 female; age 54 +/- 14 years (mean +/- SD) with bronchiectasis had a clinical assessment and spirometry performed. All were non-smokers and 84 were classified as having idiopathic disease. Patients were commenced on a standardized treatment regime and followed up for a minimum period of 2 years. On their last review when patients were clinically stable, a repeat clinical assessment and spirometry was performed and compared with the initial review. The primary endpoints measured were symptoms and FEV1. Subjects were followed up for 8.0 +/- 4.9 years. Clinical review showed that the patients had persistent symptoms that, in the case of dyspnea and sputum volume, were worse on follow-up. Spirometry showed a significant decline in FEV1 over the follow-up period with an average loss of 49 ml per year. This study showed in this group of predominantly female adult patients with bronchiectasis followed up for 8 years, patients had persistent symptoms and an excess loss in FEV1.

Entities:  

Mesh:

Year:  2005        PMID: 17136958     DOI: 10.1081/copd-200050685

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  28 in total

1.  Assessing immune function in adult bronchiectasis.

Authors:  P T King; P Hutchinson; P W Holmes; N J Freezer; V Bennett-Wood; R Robins-Browne; S R Holdsworth
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

2.  Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases.

Authors:  Guillaume Geri; Sabrina Dadoun; Tach Bui; Nuria Del Castillo Pinol; Simon Paternotte; Maxime Dougados; Laure Gossec
Journal:  BMC Infect Dis       Date:  2011-11-02       Impact factor: 3.090

Review 3.  Lung Disease in Primary Antibody Deficiencies.

Authors:  Edith Schussler; Mary B Beasley; Paul J Maglione
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Nov - Dec

4.  The effects of pulmonary rehabilitation in patients with non-cystic fibrosis bronchiectasis: protocol for a randomised controlled trial.

Authors:  Annemarie L Lee; Nola Cecins; Catherine J Hill; Anne E Holland; Linda Rautela; Robert G Stirling; Phillip J Thompson; Christine F McDonald; Sue Jenkins
Journal:  BMC Pulm Med       Date:  2010-02-02       Impact factor: 3.317

Review 5.  Airway clearance techniques for bronchiectasis.

Authors:  Annemarie L Lee; Angela T Burge; Anne E Holland
Journal:  Cochrane Database Syst Rev       Date:  2015-11-23

Review 6.  Bronchiectasis in older patients with chronic obstructive pulmonary disease : prevalence, diagnosis and therapeutic management.

Authors:  Deborah Whitters; Robert A Stockley
Journal:  Drugs Aging       Date:  2013-04       Impact factor: 3.923

7.  Bronchiectasis, part 2: Management.

Authors:  Meeta Prasad; Gregory Tino
Journal:  J Respir Dis       Date:  2008-01-01

Review 8.  Chronic Lung Disease in Primary Antibody Deficiency: Diagnosis and Management.

Authors:  Paul J Maglione
Journal:  Immunol Allergy Clin North Am       Date:  2020-06-09       Impact factor: 3.479

Review 9.  The pathophysiology of bronchiectasis.

Authors:  Paul T King
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-11-29

10.  Chronic Obstructive Pulmonary Disease as a Phenotype of Bronchiectasis for Long-Term Clinical Presentation and Treatment.

Authors:  Chih-Yi Hsu; Yan-Yuen Poon; Yu-Wei Chen; Meng-Heng Hsieh; Horng-Chyuan Lin; Wen-Feng Fang
Journal:  Medicina (Kaunas)       Date:  2021-06-05       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.